Foteini Anastasiou

Dr. Foteini Anastasiou

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2011 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
GGGreek General Practice Dyspepsia Group*
Greek General Practice Dyspepsia Group*
EOEirini Oikonomidou
Eirini Oikonomidou
FAFoteini Anastasiou
Foteini Anastasiou
IPIoannis Pilpilidis
Ioannis Pilpilidis
EKElias Kouroumalis
Elias Kouroumalis
Christos LionisChristos Lionis
Christos Lionis
Upper gastrointestinal endoscopy is the most preferable diagnostic examination for patients over fifty when upper gastrointestinal symptoms appear. However, limited knowledge exists in concerns to the compliance of primary care patients' to the doctors' recommendations for endoscopy.

10 August 2024 in Diseases
Verified
Journal Article
Open access
PDF file
Christos LionisChristos Lionis
Christos Lionis
SPSophia Papadakis
Sophia Papadakis
MAMarilena Anastasaki
Marilena Anastasaki
EAEftihis Aligizakis
Eftihis Aligizakis
FAFoteini Anastasiou
Foteini Anastasiou
ITIoanna Tsiligianni
Ioanna Tsiligianni
Background: Despite its high prevalence and impact on health, metabolic dysfunction-associated steatotic liver disease (MASLD) is inadequately addressed in European primary care (PC), with a large proportion of cases going undiagnosed or diagnosed too late. A multi-country European research consortium led a project to design and evaluate a patient-centered, integrated model for MASLD screening, diagnosis, and linkage to specialty care for European PC settings. Based on the lessons from this project, the latest research evidence, and existing guidelines for the management of MASLD, we sought to develop a set of practice recommendations for screening, referral, and management of MASLD in PC. Methods: The Rand/UCLA modified Delphi panel method, with two rounds, was used to reach consensus on practice recommendations. The international panel consisted of experts from six countries, representing family medicine, gastroenterology, hepatology, cardiology, and public health. Initially, fifteen statements were drafted based on a synthesis of evidence from the literature and earlier findings from our consortium. Prior to the consensus meeting, the statements were rated by the experts in the first round. Then, in a hybrid meeting, the experts discussed findings from round one, adjusted the statements, and reassessed the updated recommendations in a second round. Results: In round one, there was already a high level of consensus on 10 out of 15 statements. After round 2, there were fourteen statements with a high degree of agreement (>90%). One statement was not endorsed. The approved recommendations addressed the following practice areas: risk screening and diagnosis, management of MASLD–lifestyle interventions, pharmacological treatment of MASLD/MASH, pharmacological treatment for co-morbidity, integrated care, surgical management, and other referrals to specialists. Conclusions: The final set of 14 recommendations focuses on increasing comprehensive care for MASLD in PC. The recommendations provide practical evidence-based guidance tailored to PC practitioners. We expect that these recommendations will contribute to the ongoing discussion on systematic approaches to tackling MASLD and supporting European PC providers by integrating the latest evidence into practice.

27 March 2006 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
ÅFÅshild Faresjö
Åshild Faresjö
FAFoteini Anastasiou
Foteini Anastasiou
Christos LionisChristos Lionis
Christos Lionis
SJSaga Johansson
Saga Johansson
MWMari-Ann Wallander
Mari-Ann Wallander
TFTomas Faresjo
Tomas Faresjo
Persons with Irritable bowel syndrome (IBS) are seriously affected in their everyday life. The effect across different cultural settings of IBS on their quality of life has been little studied. The aim was to compare health-related quality of life (HRQOL) of individuals suffering from IBS in two different cultural settings; Crete, Greece and Linköping, Sweden.

1 January 2012 in Asia Pacific Family Medicine
Verified
Journal Article
Open access
PDF file
Christos LionisChristos Lionis
Christos Lionis
Emmanouil K SymvoulakisEmmanouil K Symvoulakis
Emmanouil K Symvoulakis
GDGeorge Duijker
George Duijker
FAFoteini Anastasiou
Foteini Anastasiou
SDStilianos Dimitrakopoulos
Stilianos Dimitrakopoulos
TVTheodoros Vasilopoulos
Theodoros Vasilopoulos
Early diagnosis of anaemia represents an important task within primary care settings. This study reports on the frequency of new cases of anaemia among patients attending rural primary care settings in Crete (Greece) and to offer an estimate of iron deficiency anaemia (IDA) frequency in this study group.

18 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Christos LionisChristos Lionis
Christos Lionis
SPSophia Papadakis
Sophia Papadakis
MAMarilena Anastasaki
Marilena Anastasaki
EAEftichios Aligizakis
Eftichios Aligizakis
FAFoteini Anastasiou
Foteini Anastasiou
ITIoanna Tsiligianni
Ioanna Tsiligianni
Introduction: Despite its high prevalence and impact on health, metabolic dysfunction-associated steatotic liver disease (MASLD) is inadequately addressed in European primary care (PC), with a large proportion of cases going undiagnosed or diagnosed too late. A multi-country European re-search consortium led a project to design and evaluate a patient-centered, integrated model for MASLD screening, diagnosis and linkage to specialty care for European PC settings. Aim: Based on the lessons from this project, the latest research evidence and existing guidelines for the management of MASLD, we sought to develop a set of practice recommendations for screening, referral and management of MASLD in PC. Methods: The Rand/UCLA modified Delphi panel method, with two rounds, was used to reach consensus on practice recommendations. The international panel consisted of experts from six countries, representing family medicine, gastroenterology, hepatology, cardiology and public health. Initially, fifteen statements were drafted based on a synthesis of evidence from the literature and earlier findings from our consortium. Prior to the consensus meeting, the statements were rated by the experts in a first round. Then, in a hybrid meeting, the experts discussed findings of round one, adjusted the statements and reassessed the updated recommendations in a second round. Results: In round one, there was already a high level of consensus on 10 out of 15 statements. After round 2, there were fourteen statements with a high agreement (>90%). One statement was not endorsed. The approved recommendations addressed the following practice areas: risk screening and diagnosis, management of MASLD – Lifestyle interventions, pharmacological treatment of MASLD/MASH, pharmacological treatment for co-morbidity, integrated care, surgical management and other referrals to specialists. Conclusion: The final set of 14 recommendations focuses on increasing comprehensive care for MASLD in PC. The recommendations provide practical evidence-based guidance tailored to PC practitioners. We expect that these recommendations will contribute to the ongoing discussion on systematic approaches to tackle MASLD and support European PC providers by integrating the latest evidence into practice.

17 April 2026 in Diseases
Verified
Journal Article
Open access
PDF file
IGIrini Gergianaki
Irini Gergianaki
FAFoteini Anastasiou
Foteini Anastasiou
SPSophia Papadakis
Sophia Papadakis
MAMarilena Anastasaki
Marilena Anastasaki
Manolis LinardakisManolis Linardakis
Manolis Linardakis
Christos LionisChristos Lionis
Christos Lionis
Objectives: The objective of this study was to investigate metabolic dysfunction-associated steatotic liver disease (MASLD)-related awareness, health literacy (HL), and illness perception among patients at risk of MASLD in European primary care settings. Methods: Participants aged ≥50 years with either obesity, metabolic syndrome (MetS), or type 2 diabetes mellitus (T2DM), and attending general practices (GPs) in Greece, Spain, or The Netherlands were included in the study. The participants completed surveys to collect data on their socio-demographic characteristics and health habits, including the European Health Literacy Survey (HLS-E-Q16), the Brief Illness Perception Questionnaire [B-IPQ], and the Public Awareness of NAFLD Questionnaire. Results: Overall, 234 patients participated in the study (mean age: 66.5 ± 9.5 years; 45.7% were male). Among the participants, 64.5%, 66.2%, and 59.8% had a diagnosis of diabetes, obesity, and MetS, respectively. Almost one-third (27.9%) had never heard about MASLD or discussed MASLD with their GP. Twelve percent (12.1%) had never heard about cirrhosis, and 20.5% were unaware that liver disorders may cause serious health problems. Overall, 43.6% of the patients had a sufficient level of HL (score >13) with a mean score of 11.5 ± 3.3. Illness perception (B-IPQ score) was low at 41.6 ± 11.6. Significantly higher B-IPQ scores were documented for female compared to male respondents (43.1 vs. 39.8; p < 0.01). Multivariate analysis found that knowledge about MASLD was associated with higher HLS-E-Q16 (p = 0.017) and B-IPQ (p = 0.028) scores. Conclusions: Despite being at risk, a significant proportion of the study participants were unaware of MASLD, its risk factors, and their personal susceptibility. This study underscores the importance of enhancing patient HL and promoting prevention and risk reduction, particularly among high-risk patient populations.